Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J N Wiley

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Peptides|January 1, 1995
Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonistsT A Pugsley, H C Akunne, S Z Whetzel, et al.
Neuropharmacology|April 13, 2000
PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effectsA E Corbin, L T Meltzer, F W Ninteman, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1992
Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonistT A Pugsley, C L Christofferson, A Corbin, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agentsJ S Sebolt-Leopold, P W Vincent, K A Beningo, et al.
Pharmaceutical Research|March 1, 1997
Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeysM R Feng, A E Corbin, Y Wang, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Peptides|January 1, 1995
Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonistsT A Pugsley, H C Akunne, S Z Whetzel, et al.
Neuropharmacology|April 13, 2000
PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effectsA E Corbin, L T Meltzer, F W Ninteman, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1992
Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonistT A Pugsley, C L Christofferson, A Corbin, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agentsJ S Sebolt-Leopold, P W Vincent, K A Beningo, et al.
Pharmaceutical Research|March 1, 1997
Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeysM R Feng, A E Corbin, Y Wang, et al.
Pageof 2